What Glenview Capital Management LLC changed, 2013 to 2026
53 quarterly 13F filings, from Q2 2013 to Q2 2026, each read from the filing itself. A quarter is compared only with the quarter before it, so a quarter with no filing is a gap in the record, not a sale.
Reported book
$5.5bn
$10.9bn at Q2 2013
Positions
45
61 at Q2 2013
Top ten weight
61%
46% at Q2 2013
Typical quarterly turnover
about 15%
Estimated from share changes
- Q2 2013: $10.9bn
- Q3 2013: $11.9bn
- Q4 2013: $14.0bn
- Q1 2014: $15.3bn
- Q2 2014: $17.3bn
- Q3 2014: $19.1bn
- Q4 2014: $20.0bn
- Q1 2015: $21.9bn
- Q2 2015: $25.3bn
- Q3 2015: $20.2bn
- Q4 2015: $17.8bn
- Q1 2016: $13.7bn
- Q2 2016: $14.1bn
- Q3 2016: $14.0bn
- Q4 2016: $14.8bn
- Q1 2017: $15.1bn
- Q2 2017: $15.4bn
- Q3 2017: $17.2bn
- Q4 2017: $18.5bn
- Q1 2018: $17.1bn
- Q2 2018: $14.7bn
- Q3 2018: $15.7bn
- Q4 2018: $10.3bn
- Q1 2019: $11.2bn
- Q2 2019: $11.0bn
- Q3 2019: $9.5bn
- Q4 2019: $11.4bn
- Q1 2020: $3.7bn
- Q2 2020: $3.6bn
- Q3 2020: $3.2bn
- Q4 2020: $4.4bn
- Q1 2021: $5.9bn
- Q2 2021: $6.0bn
- Q3 2021: $5.5bn
- Q4 2021: $4.7bn
- Q1 2022: $4.9bn
- Q2 2022: $4.0bn
- Q3 2022: $4.0bn
- Q4 2022: $4.5bn
- Q1 2023: $4.6bn
- Q2 2023: $4.4bn
- Q3 2023: $4.4bn
- Q4 2023: $4.7bn
- Q1 2024: $5.7bn
- Q2 2024: $5.1bn
- Q3 2024: $5.2bn
- Q4 2024: $4.0bn
- Q1 2025: $4.1bn
- Q2 2025: $3.6bn
- Q3 2025: $4.5bn
- Q4 2025: $4.9bn
- Q1 2026: $4.0bn
- Q2 2026: $5.5bn
- Q2 2013: 46%
- Q3 2013: 41%
- Q4 2013: 40%
- Q1 2014: 42%
- Q2 2014: 42%
- Q3 2014: 40%
- Q4 2014: 38%
- Q1 2015: 36%
- Q2 2015: 38%
- Q3 2015: 40%
- Q4 2015: 51%
- Q1 2016: 57%
- Q2 2016: 59%
- Q3 2016: 55%
- Q4 2016: 52%
- Q1 2017: 51%
- Q2 2017: 50%
- Q3 2017: 49%
- Q4 2017: 44%
- Q1 2018: 43%
- Q2 2018: 43%
- Q3 2018: 41%
- Q4 2018: 55%
- Q1 2019: 52%
- Q2 2019: 52%
- Q3 2019: 52%
- Q4 2019: 55%
- Q1 2020: 60%
- Q2 2020: 59%
- Q3 2020: 67%
- Q4 2020: 60%
- Q1 2021: 57%
- Q2 2021: 48%
- Q3 2021: 50%
- Q4 2021: 56%
- Q1 2022: 54%
- Q2 2022: 60%
- Q3 2022: 61%
- Q4 2022: 59%
- Q1 2023: 60%
- Q2 2023: 66%
- Q3 2023: 59%
- Q4 2023: 66%
- Q1 2024: 64%
- Q2 2024: 63%
- Q3 2024: 64%
- Q4 2024: 65%
- Q1 2025: 67%
- Q2 2025: 68%
- Q3 2025: 65%
- Q4 2025: 60%
- Q1 2026: 61%
- Q2 2026: 61%
The positions that defined it
Every position that was ever among the 25 largest: when it first appeared, when it was largest, and where it stands in Q2 2026. The line is its reported value each quarter.
| Position | Value over time | First listed | Largest | Q2 2026 |
|---|---|---|---|---|
| Global PMTS Inc(GPN) | Q3 2013 | $646mQ2 2026 | $646m | |
| CVS Health Corp(CVS) | Q3 2017 | $809mQ1 2025 | $499m | |
| Tenet Healthcare Corp(THC) | Q2 2013 | $856mQ2 2015 | $418m | |
| Thermo Fisher Scientific Inc(TMO) | Q2 2013 | $1.4bnQ4 2014 | $314m | |
| Amazon Com Inc(AMZN) | Q4 2020 | $303mQ2 2026 | $303m | |
| iShares Russell 2000 ETF(IWM) | Q2 2023 | $319mQ4 2023 | $276m | |
| Agilent Technologies Inc(A) | Q3 2015 | $262mQ2 2026 | $262m | |
| Danaher Corp Del(DHR) | Q3 2014 | $429mQ4 2014 | $218m | |
| Facebook Inc(META)Class A | Q1 2018 | $201mQ2 2026 | $201m | |
| Spdr S&P 500 Etf Trust(SPY) | Q4 2022 | $532mQ2 2023 | $194m | |
| Advanced Micro Devices Inc(AMD) | Q4 2025 | $173mQ2 2026 | $173m | |
| Teva Pharmaceutical Inds LTD(TEVA)Sponsored ADS | Q4 2023 | $522mQ4 2025 | $172m | |
| Monsanto Co New | Q3 2013 | $1.4bnQ4 2015 | Soldlast listed Q4 2017 | |
| Hca Holdings Inc(HCA) | Q2 2013 | $1.3bnQ4 2016 | Soldlast listed Q2 2024 | |
| Dowdupont Inc | Q3 2017 | $1.1bnQ3 2017 | Soldlast listed Q4 2018 | |
| F M C Corp(FMC) | Q1 2015 | $1.0bnQ3 2017 | Soldlast listed Q4 2024 | |
| Cigna Corporation | Q2 2013 | $1.0bnQ4 2015 | Soldlast listed Q3 2018 | |
| Flextronics Intl LTD(FLEX) | Q2 2013 | $952mQ1 2015 | Soldlast listed Q2 2023 | |
| Shire PLCSponsored ADR | Q1 2017 | $899mQ3 2017 | Soldlast listed Q4 2018 | |
| Dow Chem Co | Q3 2014 | $897mQ2 2017 | Soldlast listed Q2 2017 |
Quarter by quarter
Q1 2026: $4.0bn across 44 positions
Against Q4 2025: 9 new, 17 added to, 15 trimmed, 22 sold out, across all 44 positions.
Turnover about 20% of the book, estimated from share changes at quarter-end prices.
Largest additions
- Facebook Inc (META)+$63m
- Cigna Corp New (CI)+$56m
- Advanced Micro Devices Inc (AMD)+$48m
- Uber Technologies Inc (UBER)+$47m
- Applied Matls Inc (AMAT)+$34m
- Centene Corp Del (CNC)+$29m
- Block Inc (XYZ)+$27m
- Six Flags Entertainment Corp (FUN)+$22m
Largest reductions
- Teva Pharmaceutical Inds LTD (TEVA)-$321m
- Zoominfo Technologies Inc (GTM)-$108m
- Tenet Healthcare Corp (THC)-$106m
- Digitalocean HLDGS Inc (DOCN)-$75m
- US Foods HLDG Corp (USFD)-$50m
- Zillow Group Inc (Z)-$47m
- Lionsgate Studios Corp (LION)-$42m
- Biogen Inc (BIIB)-$41m
Opened
- Invesco QQQ Trust (QQQ)$189m
- iShares Russell 2000 ETF (IWM)$93m
- Humana Inc (HUM)$58m
Sold out
- iShares Trust (HYG)was $143m
- Expedia Group Inc (EXPE)was $91m
- Knight-swift Transn HLDGS In (KNX)was $76m
- iShares Trust (TLT)was $54m
- Accenture PLC Ireland (ACN)was $51m
- Iqvia HLDGS Inc (IQV)was $45m
- Qnity Electronics Inc (Q)was $42m
- Mckesson Corp (MCK)was $35m
Largest positions, Q1 2026
The largest 25 of 44 reported positions.
| Position | Value | Weight | On the quarter |
|---|---|---|---|
| CVS Health Corp (CVS) | $589m | 14.8% | Held |
| Global PMTS Inc (GPN) | $428m | 10.7% | Added |
| Tenet Healthcare Corp (THC) | $288m | 7.2% | Trimmed |
| Amazon Com Inc (AMZN) | $221m | 5.5% | Added |
| Teva Pharmaceutical Inds LTD (TEVA) | $201m | 5.0% | Trimmed |
| Invesco QQQ Trust (QQQ) | $189m | 4.8% | New |
| Cigna Corp New (CI) | $133m | 3.3% | Added |
| Advanced Micro Devices Inc (AMD) | $132m | 3.3% | Added |
| Thermo Fisher Scientific Inc (TMO) | $123m | 3.1% | Added |
| Viatris Inc (VTRS) | $123m | 3.1% | Trimmed |
| DXC Technology Co (DXC) | $112m | 2.8% | Added |
| Centene Corp Del (CNC) | $105m | 2.6% | Added |
| Uber Technologies Inc (UBER) | $105m | 2.6% | Added |
| Zoominfo Technologies Inc (GTM) | $95m | 2.4% | Trimmed |
| iShares Russell 2000 ETF (IWM) | $93m | 2.3% | New |
| Block Inc (XYZ) | $82m | 2.1% | Added |
| Facebook Inc (META) | $70m | 1.8% | Added |
| Applied Matls Inc (AMAT) | $67m | 1.7% | Added |
| Onto Innovation Inc (ONTO) | $61m | 1.5% | Trimmed |
| Dicks Sporting Goods Inc (DKS) | $59m | 1.5% | Added |
| Humana Inc (HUM) | $58m | 1.5% | New |
| Butterfly Network Inc (BFLY) | $58m | 1.5% | Held |
| Element Solutions Inc (ESI) | $56m | 1.4% | Trimmed |
| United Airls HLDGS Inc (UAL) | $46m | 1.1% | Trimmed |
| National Vision HLDGS Inc (EYE) | $41m | 1.0% | Added |
The books most like this one
Among the managers whose filings are on file, at Q2 2026. Overlap is the share of the two books that is the same: for every stock both list, the smaller of its two weights, added up. Two books can overlap because both own the largest companies; it says nothing about whether the managers agree.
| Manager | Overlap | Stocks in both | Overlap over time | |
|---|---|---|---|---|
| Capital Research Global Investors | 14% | 18 | Compare | |
| Tiger Global Management LLC | 14% | 7 | Compare | |
| Holocene Advisors LP | at least 13% | 21 | Compare | |
| Maverick Capital Ltd | 13% | 15 | Compare | |
| Appaloosa LP | 13% | 4 | Compare | |
| Altimeter Capital Management LP | 12% | 4 | Compare | |
| Dodge & Cox | 12% | 16 | Compare | |
| T. Rowe Price Associates Inc | at least 12% | 27 | Compare |
“At least” where either manager has more positions than are read each quarter: a stock both hold below that range is not counted.
The filings behind it
Every quarter above is one 13F holdings report, with any amendment the filer made to it applied in the order it was filed. Where the reporting entity changed, each quarter keeps the filer that actually reported it.
| Quarter | Filer | Book | Amended | Filing |
|---|---|---|---|---|
| Q2 2026 | Glenview Capital Management LLC | $5.5bn | 13F-HR | |
| Q1 2026 | Glenview Capital Management LLC | $4.0bn | 13F-HR | |
| Q4 2025 | Glenview Capital Management LLC | $4.9bn | 13F-HR | |
| Q3 2025 | Glenview Capital Management LLC | $4.5bn | 13F-HR | |
| Q2 2025 | Glenview Capital Management LLC | $3.6bn | 13F-HR | |
| Q1 2025 | Glenview Capital Management LLC | $4.1bn | 13F-HR | |
| Q4 2024 | Glenview Capital Management LLC | $4.0bn | 13F-HR | |
| Q3 2024 | Glenview Capital Management LLC | $5.2bn | 13F-HR | |
| Q2 2024 | Glenview Capital Management LLC | $5.1bn | 13F-HR | |
| Q1 2024 | Glenview Capital Management LLC | $5.7bn | 13F-HR | |
| Q4 2023 | Glenview Capital Management LLC | $4.7bn | 13F-HR | |
| Q3 2023 | Glenview Capital Management LLC | $4.4bn | 13F-HR | |
| Q2 2023 | Glenview Capital Management LLC | $4.4bn | 13F-HR | |
| Q1 2023 | Glenview Capital Management LLC | $4.6bn | 13F-HR | |
| Q4 2022 | Glenview Capital Management LLC | $4.5bn | 13F-HR | |
| Q3 2022 | Glenview Capital Management LLC | $4.0bn | 13F-HR | |
| Q2 2022 | Glenview Capital Management LLC | $4.0bn | 13F-HR | |
| Q1 2022 | Glenview Capital Management LLC | $4.9bn | 13F-HR | |
| Q4 2021 | Glenview Capital Management LLC | $4.7bn | 13F-HR | |
| Q3 2021 | Glenview Capital Management LLC | $5.5bn | 1 | 13F-HR |
| Q2 2021 | Glenview Capital Management LLC | $6.0bn | 13F-HR | |
| Q1 2021 | Glenview Capital Management LLC | $5.9bn | 13F-HR | |
| Q4 2020 | Glenview Capital Management LLC | $4.4bn | 13F-HR | |
| Q3 2020 | Glenview Capital Management LLC | $3.2bn | 13F-HR | |
| Q2 2020 | Glenview Capital Management LLC | $3.6bn | 13F-HR | |
| Q1 2020 | Glenview Capital Management LLC | $3.7bn | 13F-HR | |
| Q4 2019 | Glenview Capital Management LLC | $11.4bn | 13F-HR | |
| Q3 2019 | Glenview Capital Management LLC | $9.5bn | 13F-HR | |
| Q2 2019 | Glenview Capital Management LLC | $11.0bn | 13F-HR | |
| Q1 2019 | Glenview Capital Management LLC | $11.2bn | 13F-HR | |
| Q4 2018 | Glenview Capital Management LLC | $10.3bn | 13F-HR | |
| Q3 2018 | Glenview Capital Management LLC | $15.7bn | 13F-HR | |
| Q2 2018 | Glenview Capital Management LLC | $14.7bn | 13F-HR | |
| Q1 2018 | Glenview Capital Management LLC | $17.1bn | 13F-HR | |
| Q4 2017 | Glenview Capital Management LLC | $18.5bn | 13F-HR | |
| Q3 2017 | Glenview Capital Management LLC | $17.2bn | 13F-HR | |
| Q2 2017 | Glenview Capital Management LLC | $15.4bn | 13F-HR | |
| Q1 2017 | Glenview Capital Management LLC | $15.1bn | 13F-HR | |
| Q4 2016 | Glenview Capital Management LLC | $14.8bn | 13F-HR | |
| Q3 2016 | Glenview Capital Management LLC | $14.0bn | 13F-HR | |
| Q2 2016 | Glenview Capital Management LLC | $14.1bn | 13F-HR | |
| Q1 2016 | Glenview Capital Management LLC | $13.7bn | 13F-HR | |
| Q4 2015 | Glenview Capital Management LLC | $17.8bn | 13F-HR | |
| Q3 2015 | Glenview Capital Management LLC | $20.2bn | 13F-HR | |
| Q2 2015 | Glenview Capital Management LLC | $25.3bn | 13F-HR | |
| Q1 2015 | Glenview Capital Management LLC | $21.9bn | 13F-HR | |
| Q4 2014 | Glenview Capital Management LLC | $20.0bn | 13F-HR | |
| Q3 2014 | Glenview Capital Management LLC | $19.1bn | 13F-HR | |
| Q2 2014 | Glenview Capital Management LLC | $17.3bn | 13F-HR | |
| Q1 2014 | Glenview Capital Management LLC | $15.3bn | 13F-HR | |
| Q4 2013 | Glenview Capital Management LLC | $14.0bn | 13F-HR | |
| Q3 2013 | Glenview Capital Management LLC | $11.9bn | 13F-HR | |
| Q2 2013 | Glenview Capital Management LLC | $10.9bn | 13F-HR |
Reading this record
A 13F lists US-listed long equity and options at the quarter end, filed up to 45 days later. It shows what was held, not when it was bought or at what price, and nothing short. Where a quarter lists only the largest positions, a name missing from it may still be held below that range; the counts of what was opened and sold always cover the whole filing.
Company names, tickers and logos are the trademarks of their respective owners and appear here to identify the company whose public figures are being used. L3VLUP is not affiliated with, sponsored by or endorsed by any company shown, and nothing here is a statement by or about that company. More